Mama Bird Launches in Sprouts Farmers Market Nationwide With Brain-First Supplements for Families
Science-Backed Prenatal & Kids Vitamins Launch in Retail
DENVER, June 12, 2025 (GLOBE NEWSWIRE) -- Mama Bird® is hatching at Sprouts this season! Mama Bird, maker of brain-boosting vitamins for families, is excited to announce that four of its best-selling prenatal and kids' vitamins are now available at Sprouts Farmers Market for a limited time in stores nationwide.Created by neurologist Dr. Mika Gupta and inspired by her own parenting journey, Mama Bird is on a mission to support cognitive health from the very beginning — helping families feel confident they're nourishing themselves and their children for a smarter start.
'Our goal is to make it easy for families to turn everyday moments into opportunities for meaningful growth,' said Dr. Gupta, founder of Mama Bird. 'We're proud to launch at Sprouts, a retailer that shares our values around wellness, transparency, and smarter nutrition.'
The following four Mama Bird supplements are now available in all Sprouts stores:
Mama Bird Prenatal Multi+ – A once-daily tablet with brain-focused, methylated nutrients to support fetal brain development and maternal wellness.
Mama Bird Pre+Postnatal DHA – A mercury-free omega-3 supplement with DHA to support brain and eye development during pregnancy and postpartum.
Mama Bird Kids Multi+ Liquid – A fast-absorbing, strawberry-flavored liquid multivitamin with methylated B vitamins to support cognitive development in growing kids.
Mama Bird Kids Multi+ Gummies – Sensory-friendly, raspberry-flavored gummies with essential brain-supportive nutrients and no artificial dyes or flavors.
Previously known as Best Nest Wellness since 2015, the company recently rebranded to Mama Bird to reflect its mission: supporting families through brain-first nutrition and the small moments that shape a child's future.
Mama Bird was created to make brain-first nutrition easy, accessible, and aligned with real life. Every product is formulated with bioavailable, brain-supportive nutrients — including methylated B vitamins — and delivered in clean, gentle formats designed for maximum absorption without the stress and overwhelm of traditional supplements.
Mama Bird products are now available at Sprouts Farmers Market stores nationwide as part of the Innovation Center — a 90-day program that spotlights emerging wellness brands in Sprouts' dedicated 'New for You' section.
Learn more at lovemamabird.com.
About Mama BirdMama Bird is the first supplement brand built around brain-first nutrition for pregnancy, postpartum, and childhood. With carefully selected, highly absorbable ingredients that support cognitive wellness, Mama Bird empowers families to nurture bright minds from the very beginning. Learn more at lovemamabird.com and follow on Instagram, Facebook, TikTok, and YouTube.
About Sprouts Farmers Market, Inc.True to its farm-stand heritage, Sprouts offers a unique grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspires wellness naturally with a carefully curated assortment of better-for-you products paired with purpose-driven people. The healthy grocer continues to bring the latest in wholesome, innovative products made with lifestyle-friendly ingredients such as organic, plant-based and gluten-free. Headquartered in Phoenix, and one of the largest and fastest growing specialty retailers of fresh, natural and organic food in the United States, Sprouts employs approximately 35,000 team members and operates more than 440 stores in 24 states nationwide. To learn more about Sprouts, and the good it brings communities, visit sprouts.com/about.
MEDIA CONTACT: Lisa Lazarczyk, LAZ PRTel: 617.838.7327 or lisa@lazpr.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7bb06cbd-3361-4ba9-8e2b-5c57a2f0bee7
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare
Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13, 2025 /PRNewswire/ -- The Berwyn Group (Berwyn), the leader in death audit, locate services and population management, is pleased to announce the hiring of Adam Wilson as General Manager of Healthcare. Wilson brings extensive healthcare industry experience that will further strengthen Berwyn's commitment to excellence and growth. Berwyn offers an end-to-end suite of industry-leading death audit and locate solutions that enable pension and health plan administrators to eliminate costly overpayments, maximize efficiency, meet regulatory requirements, and connect policyholders, participants and beneficiaries to the funds they deserve. More than 2,000 corporate, union and government clients use Berwyn's flagship services, CertiDeath® and CertiCensus®. Wilson joins Berwyn with a distinguished career that spans almost 17 years at UnitedHealthcare, where he held several leadership roles including Vice President of Workforce Planning, Chief of Staff to the COO, and Vice President of Medicare Part D products. "We are thrilled to welcome Adam to the team," said John Bikus, President of Berwyn. "His strategy, proven leadership, and deep industry knowledge will be invaluable as we continue to grow in the healthcare industry." In his new role, Wilson will be responsible for leading Berwyn's strategic expansion into the healthcare market. He will be focusing on aligning Berwyn's solutions to the healthcare payer and provider business cycle needs while also extending the Berwyn reach to healthcare-related supporting partners, vendors, and industry trade groups. "I'm eager to join an organization positioned for rapid growth through industry-leading capabilities," said Wilson. "I look forward to collaborating with the talented team at Berwyn to deliver quick wins, strategic expansion into healthcare, and contribute to the company's continued success." About The Berwyn Group The Berwyn Group is the leader in population data management, offering the industry's most trusted and effective death audit and locate solutions, with an unmatched dedication to innovation, security, and generating outcomes. Acquired by Longevity Holdings in 2023, The Berwyn Group offers an end-to-end suite of industry-leading solutions including CertiDeath® Paragon™, CertiDeath®, CertiCensus®, CertiSearch® and BeneSearch®. Connecting leading-edge technology and data with best-in-class human ingenuity, Berwyn helps bridge the gap between pensions and their participants, insurance companies and their policyholders, third-party administrators and public entities with Medicaid recipients. For more information, visit Media Contact Karlene Gilmore Director of Marketing kgilmore@ View original content: SOURCE The Berwyn Group, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®
BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture and factory automation markets, is proud to announce the certification of the Memor 17 Healthcare mobile computer with OncoSafety Remote Control®, the advanced oncology workflow solution developed by B. Braun, a global leader in smart infusion therapy and healthcare technology. This integration combines Datalogic's most advanced healthcare-grade mobile computer with B. Braun's OncoSafety Remote Control®, enabling unmatched traceability, medication accuracy, and compliance in oncology treatment. Together, these technologies deliver a safer, more efficient experience for healthcare professionals and patients alike. Designed for front-line healthcare, the Memor 17 Healthcare features 5G connectivity, Wi-Fi 6E, and an ultra-rugged, disinfectant-ready design. The integrated Halogen™ 2121DL scan engine ensures fast and accurate barcode capture – even on damaged or poorly printed labels – while Datalogic's signature Green Spot technology provides silent scan confirmation, ideal for quiet zones such as neonatal wards or intensive care units. The certification with OncoSafety Remote Control® extends the capabilities of the Memor 17 Healthcare across oncology workflows – from bedside medication administration to remote patient visits – ensuring the highest standards of patient safety, data access, and workflow efficiency. The Memor 17 Healthcare also supports programmable emergency alerts and custom gestures, allowing clinical staff to trigger safety protocols instantly. With long-term Android™ support (version 18 and beyond), AI-powered software tools from the Datalogic Mobility Suite, and a slim, ergonomic form factor, this device is ready to meet the evolving needs of healthcare environments. "The Memor 17 Healthcare sets a new benchmark for patient care and safety in oncology," said Rosario Casillo, Data Capture Product and Solutions Executive VP at Datalogic. "Its certification with B. Braun's OncoSafety Remote Control® enables seamless verification of patient-treatment matching with their advanced solution, ensuring healthcare professionals can rely on a connected, secure, and highly functional device to deliver critical care wherever it's needed." "Our mission at B. Braun is to protect and improve the health of people around the world. We are pleased to collaborate with Datalogic to equip caregivers with the technology needed to make well-informed decisions and reduce medication errors," added Thore Heinemann, Senior Digital Solution Manager at B. Braun. Datalogic GroupA global technology leader in the automatic data capture and industrial automation markets since 1972, specializes in the design and production of barcode readers, mobile computers, sensors for detection, measurement and safety, machine vision and laser marking systems. These products and solutions enhance efficiency and quality across the entire value chain, in industries such as retail, manufacturing, transportation and logistics, and healthcare. Trusted by major global players in its four target sectors, Datalogic is recognized for its customer focus and commitment to quality, upheld by the Group for over 50 years. Today, Datalogic Group, headquartered in Bologna (Italy), employs approximately 2,700 staff worldwide, distributed in 27 countries, with 10 manufacturing and repair facilities in the U.S.A., Hungary, Slovakia, Italy, China, and Vietnam, 10 Research & Development centers and 3 DL Labs in Italy, U.S.A., Vietnam, and Czech Republic. In 2024, Datalogic Group recorded sales of € 493.8 million and invested € 65.9 million in R&D. Datalogic S.p.A. has been listed in the Euronext STAR Milan segment of the Italian Stock Exchange since 2001 as Visit Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U. Other trademarks belong to their respective owners. B. Braun B. Braun is one of the world's leading providers and manufacturers of healthcare solutions developing innovative products and services in smart infusion therapy, anesthesia, intensive care, and oncology. Through partnerships and digital technologies like OncoSafety Remote Control®, B. Braun supports safer, more effective clinical outcomes. View original content: SOURCE Datalogic Sign in to access your portfolio


Business Wire
a day ago
- Business Wire
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM ® RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher's industry-leading end-to-end GMP-compliant manufacturing capabilities. Broadening global access to Ethris' comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept. 'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,' said Dr. Carsten Rudolph, CEO of Ethris. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.' The collaboration will also support the continued optimization of Ethris' platform technologies, which have already demonstrated positive pharmacodynamic effects, safety and targeted engagement in Phase 1 topline data of its lead candidate, ETH47. Designed for local administration via nasal spray to address the upstream trigger of asthma exacerbations, ETH47 showed dose-dependent, localized production of the encoded protein, interferon lambda at the site of administration, with no systemic bioavailability. The study confirmed that ETH47 activated downstream signaling, demonstrating the expressed protein's functional activity. Given its non-immunogenic nature, SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines. 'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,' said Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.' Ethris' SNIM® RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines. About Ethris Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. For more information, visit